|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BIRC5 |
Gene summary for BIRC5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BIRC5 | Gene ID | 332 |
| Gene name | baculoviral IAP repeat containing 5 | |
| Gene Alias | API4 | |
| Cytomap | 17q25.3 | |
| Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | O15392 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 332 | BIRC5 | GSM4909281 | Human | Breast | IDC | 1.43e-12 | 3.80e-01 | 0.21 |
| 332 | BIRC5 | GSM4909282 | Human | Breast | IDC | 6.67e-33 | 7.13e-01 | -0.0288 |
| 332 | BIRC5 | GSM4909285 | Human | Breast | IDC | 1.76e-02 | 1.06e-01 | 0.21 |
| 332 | BIRC5 | GSM4909287 | Human | Breast | IDC | 7.71e-15 | 5.45e-01 | 0.2057 |
| 332 | BIRC5 | GSM4909290 | Human | Breast | IDC | 2.81e-08 | 4.34e-01 | 0.2096 |
| 332 | BIRC5 | GSM4909291 | Human | Breast | IDC | 6.95e-08 | 3.92e-01 | 0.1753 |
| 332 | BIRC5 | GSM4909304 | Human | Breast | IDC | 2.60e-02 | 1.33e-01 | 0.1636 |
| 332 | BIRC5 | GSM4909307 | Human | Breast | IDC | 4.12e-02 | 1.75e-01 | 0.1569 |
| 332 | BIRC5 | GSM4909319 | Human | Breast | IDC | 2.93e-03 | 2.74e-01 | 0.1563 |
| 332 | BIRC5 | M2 | Human | Breast | IDC | 2.64e-12 | 9.23e-01 | 0.21 |
| 332 | BIRC5 | P2 | Human | Breast | IDC | 7.47e-06 | 4.65e-01 | 0.21 |
| 332 | BIRC5 | LZE2T | Human | Esophagus | ESCC | 1.04e-05 | 1.01e+00 | 0.082 |
| 332 | BIRC5 | LZE6T | Human | Esophagus | ESCC | 1.27e-04 | 4.88e-01 | 0.0845 |
| 332 | BIRC5 | P2T-E | Human | Esophagus | ESCC | 3.46e-10 | 7.17e-01 | 0.1177 |
| 332 | BIRC5 | P4T-E | Human | Esophagus | ESCC | 1.95e-15 | 6.54e-01 | 0.1323 |
| 332 | BIRC5 | P5T-E | Human | Esophagus | ESCC | 2.88e-14 | 5.58e-01 | 0.1327 |
| 332 | BIRC5 | P8T-E | Human | Esophagus | ESCC | 8.54e-03 | 2.77e-01 | 0.0889 |
| 332 | BIRC5 | P9T-E | Human | Esophagus | ESCC | 9.37e-11 | 5.54e-01 | 0.1131 |
| 332 | BIRC5 | P10T-E | Human | Esophagus | ESCC | 5.62e-14 | 8.06e-01 | 0.116 |
| 332 | BIRC5 | P15T-E | Human | Esophagus | ESCC | 1.22e-08 | 6.50e-01 | 0.1149 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005254714 | Breast | IDC | regulation of peptidase activity | 96/1434 | 461/18723 | 7.58e-20 | 6.15e-17 | 96 |
| GO:005254814 | Breast | IDC | regulation of endopeptidase activity | 88/1434 | 432/18723 | 1.20e-17 | 4.85e-15 | 88 |
| GO:200011614 | Breast | IDC | regulation of cysteine-type endopeptidase activity | 55/1434 | 235/18723 | 4.25e-14 | 1.21e-11 | 55 |
| GO:004586114 | Breast | IDC | negative regulation of proteolysis | 70/1434 | 351/18723 | 8.21e-14 | 2.22e-11 | 70 |
| GO:004328114 | Breast | IDC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 50/1434 | 209/18723 | 2.49e-13 | 6.14e-11 | 50 |
| GO:005134613 | Breast | IDC | negative regulation of hydrolase activity | 71/1434 | 379/18723 | 1.33e-12 | 2.90e-10 | 71 |
| GO:001046613 | Breast | IDC | negative regulation of peptidase activity | 56/1434 | 262/18723 | 1.39e-12 | 2.92e-10 | 56 |
| GO:001095112 | Breast | IDC | negative regulation of endopeptidase activity | 52/1434 | 252/18723 | 3.53e-11 | 5.57e-09 | 52 |
| GO:200011713 | Breast | IDC | negative regulation of cysteine-type endopeptidase activity | 25/1434 | 86/18723 | 3.31e-09 | 2.77e-07 | 25 |
| GO:004315413 | Breast | IDC | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 22/1434 | 78/18723 | 5.26e-08 | 3.32e-06 | 22 |
| GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
| GO:2000116111 | Esophagus | ESCC | regulation of cysteine-type endopeptidase activity | 158/8552 | 235/18723 | 1.67e-11 | 5.90e-10 | 158 |
| GO:0043281111 | Esophagus | ESCC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 143/8552 | 209/18723 | 2.12e-11 | 7.31e-10 | 143 |
| GO:0052547111 | Esophagus | ESCC | regulation of peptidase activity | 275/8552 | 461/18723 | 7.54e-10 | 1.88e-08 | 275 |
| GO:0052548111 | Esophagus | ESCC | regulation of endopeptidase activity | 253/8552 | 432/18723 | 3.68e-08 | 6.78e-07 | 253 |
| GO:003150314 | Esophagus | ESCC | protein-containing complex localization | 139/8552 | 220/18723 | 1.14e-07 | 1.85e-06 | 139 |
| GO:2000117110 | Esophagus | ESCC | negative regulation of cysteine-type endopeptidase activity | 63/8552 | 86/18723 | 1.84e-07 | 2.88e-06 | 63 |
| GO:0043154110 | Esophagus | ESCC | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 58/8552 | 78/18723 | 2.38e-07 | 3.61e-06 | 58 |
| GO:0045861111 | Esophagus | ESCC | negative regulation of proteolysis | 195/8552 | 351/18723 | 1.13e-04 | 7.85e-04 | 195 |
| GO:0051346110 | Esophagus | ESCC | negative regulation of hydrolase activity | 208/8552 | 379/18723 | 1.76e-04 | 1.14e-03 | 208 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0421022 | Breast | IDC | Apoptosis | 31/867 | 136/8465 | 1.34e-05 | 1.61e-04 | 1.20e-04 | 31 |
| hsa052109 | Breast | IDC | Colorectal cancer | 17/867 | 86/8465 | 5.70e-03 | 3.13e-02 | 2.34e-02 | 17 |
| hsa0421032 | Breast | IDC | Apoptosis | 31/867 | 136/8465 | 1.34e-05 | 1.61e-04 | 1.20e-04 | 31 |
| hsa0521014 | Breast | IDC | Colorectal cancer | 17/867 | 86/8465 | 5.70e-03 | 3.13e-02 | 2.34e-02 | 17 |
| hsa0421027 | Esophagus | ESCC | Apoptosis | 102/4205 | 136/8465 | 1.05e-09 | 1.21e-08 | 6.21e-09 | 102 |
| hsa0521020 | Esophagus | ESCC | Colorectal cancer | 69/4205 | 86/8465 | 4.06e-09 | 4.13e-08 | 2.11e-08 | 69 |
| hsa015247 | Esophagus | ESCC | Platinum drug resistance | 56/4205 | 73/8465 | 1.85e-06 | 1.13e-05 | 5.78e-06 | 56 |
| hsa051619 | Esophagus | ESCC | Hepatitis B | 108/4205 | 162/8465 | 7.68e-06 | 4.15e-05 | 2.12e-05 | 108 |
| hsa042156 | Esophagus | ESCC | Apoptosis - multiple species | 25/4205 | 32/8465 | 9.13e-04 | 2.92e-03 | 1.49e-03 | 25 |
| hsa0439018 | Esophagus | ESCC | Hippo signaling pathway | 92/4205 | 157/8465 | 1.46e-02 | 3.31e-02 | 1.69e-02 | 92 |
| hsa0421037 | Esophagus | ESCC | Apoptosis | 102/4205 | 136/8465 | 1.05e-09 | 1.21e-08 | 6.21e-09 | 102 |
| hsa05210110 | Esophagus | ESCC | Colorectal cancer | 69/4205 | 86/8465 | 4.06e-09 | 4.13e-08 | 2.11e-08 | 69 |
| hsa0152414 | Esophagus | ESCC | Platinum drug resistance | 56/4205 | 73/8465 | 1.85e-06 | 1.13e-05 | 5.78e-06 | 56 |
| hsa0516114 | Esophagus | ESCC | Hepatitis B | 108/4205 | 162/8465 | 7.68e-06 | 4.15e-05 | 2.12e-05 | 108 |
| hsa0421511 | Esophagus | ESCC | Apoptosis - multiple species | 25/4205 | 32/8465 | 9.13e-04 | 2.92e-03 | 1.49e-03 | 25 |
| hsa0439019 | Esophagus | ESCC | Hippo signaling pathway | 92/4205 | 157/8465 | 1.46e-02 | 3.31e-02 | 1.69e-02 | 92 |
| hsa0521022 | Liver | HCC | Colorectal cancer | 65/4020 | 86/8465 | 8.85e-08 | 1.23e-06 | 6.87e-07 | 65 |
| hsa015242 | Liver | HCC | Platinum drug resistance | 52/4020 | 73/8465 | 3.14e-05 | 1.88e-04 | 1.04e-04 | 52 |
| hsa042102 | Liver | HCC | Apoptosis | 83/4020 | 136/8465 | 9.51e-04 | 3.58e-03 | 1.99e-03 | 83 |
| hsa051612 | Liver | HCC | Hepatitis B | 91/4020 | 162/8465 | 1.56e-02 | 3.76e-02 | 2.09e-02 | 91 |
| Page: 1 2 3 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BIRC5 | SNV | Missense_Mutation | rs146071276 | c.253N>C | p.Thr85Pro | p.T85P | protein_coding | deleterious_low_confidence(0.02) | benign(0) | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | |
| BIRC5 | SNV | Missense_Mutation | c.292N>C | p.Glu98Gln | p.E98Q | protein_coding | tolerated(0.16) | benign(0.033) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
| BIRC5 | SNV | Missense_Mutation | novel | c.11C>T | p.Pro4Leu | p.P4L | protein_coding | tolerated(0.11) | benign(0.047) | TCGA-VS-A9V3-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
| BIRC5 | SNV | Missense_Mutation | rs267605071 | c.76C>T | p.Pro26Ser | p.P26S | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| BIRC5 | SNV | Missense_Mutation | c.38N>C | p.Phe13Ser | p.F13S | protein_coding | tolerated(0.05) | benign(0.01) | TCGA-QG-A5Z2-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
| BIRC5 | SNV | Missense_Mutation | rs115296168 | c.227N>T | p.Pro76Leu | p.P76L | protein_coding | tolerated_low_confidence(0.1) | possibly_damaging(0.859) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| BIRC5 | SNV | Missense_Mutation | c.220N>G | p.Ile74Val | p.I74V | protein_coding | tolerated(0.73) | benign(0.006) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| BIRC5 | SNV | Missense_Mutation | c.230N>A | p.Gly77Asp | p.G77D | protein_coding | tolerated_low_confidence(0.32) | benign(0.09) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| BIRC5 | SNV | Missense_Mutation | rs201354179 | c.452N>T | p.Ala151Val | p.A151V | protein_coding | tolerated(0.34) | probably_damaging(0.923) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| BIRC5 | SNV | Missense_Mutation | c.196G>T | p.Gly66Cys | p.G66C | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-55-8511-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 332 | BIRC5 | DRUG RESISTANCE, TUMOR SUPPRESSOR, PROTEASE INHIBITOR, DRUGGABLE GENOME | PACLITAXEL | PACLITAXEL | ||
| 332 | BIRC5 | DRUG RESISTANCE, TUMOR SUPPRESSOR, PROTEASE INHIBITOR, DRUGGABLE GENOME | RAS INHIBITOR | 16985068 | ||
| 332 | BIRC5 | DRUG RESISTANCE, TUMOR SUPPRESSOR, PROTEASE INHIBITOR, DRUGGABLE GENOME | DPX-Survivac | |||
| 332 | BIRC5 | DRUG RESISTANCE, TUMOR SUPPRESSOR, PROTEASE INHIBITOR, DRUGGABLE GENOME | IL-12 | 12895357 | ||
| 332 | BIRC5 | DRUG RESISTANCE, TUMOR SUPPRESSOR, PROTEASE INHIBITOR, DRUGGABLE GENOME | PACLITAXEL | PACLITAXEL | 16211241,15347474 | |
| 332 | BIRC5 | DRUG RESISTANCE, TUMOR SUPPRESSOR, PROTEASE INHIBITOR, DRUGGABLE GENOME | PMA | 12118374 | ||
| 332 | BIRC5 | DRUG RESISTANCE, TUMOR SUPPRESSOR, PROTEASE INHIBITOR, DRUGGABLE GENOME | CALCITONIN | CALCITONIN | 16222118 | |
| 332 | BIRC5 | DRUG RESISTANCE, TUMOR SUPPRESSOR, PROTEASE INHIBITOR, DRUGGABLE GENOME | FLUTAMIDE | FLUTAMIDE | 15735703 | |
| 332 | BIRC5 | DRUG RESISTANCE, TUMOR SUPPRESSOR, PROTEASE INHIBITOR, DRUGGABLE GENOME | ADM | 17121723 | ||
| 332 | BIRC5 | DRUG RESISTANCE, TUMOR SUPPRESSOR, PROTEASE INHIBITOR, DRUGGABLE GENOME | LY2181308 | GATAPARSEN |
| Page: 1 2 3 4 5 6 7 8 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |